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Enzymes capable of inactivating tetracycline are
paradoxically rare comparedwith enzymes that inac-
tivate other natural-product antibiotics. We describe
a family of flavoenzymes, previously unrecognizable
as resistance genes, which are capable of degrading
tetracycline antibiotics. From soil functional metage-
nomic selections, we discovered nine genes that
confer high-level tetracycline resistance by enzy-
matic inactivation. We also demonstrate that a tenth
enzyme, an uncharacterized homolog in the human
pathogen Legionella longbeachae, similarly inacti-
vates tetracycline. These enzymes catalyze the
oxidation of tetracyclines in vitro both by known
mechanisms and via previously undescribed activity.
Tetracycline-inactivation genes were identified in
diverse soil types, encompass substantial sequence
diversity, and are adjacent to genes implicated in
horizontal gene transfer. Because tetracycline inac-
tivation is scarcely observed in hospitals, these
enzymes may fill an empty niche in pathogenic or-
ganisms, and should therefore be monitored for their
dissemination potential into the clinic.
INTRODUCTION
Since their discovery from extracts of Streptomyces aureofa-
ciens in 1948, the tetracyclines have become one of the most
widely used classes of antibiotics in agriculture, aquaculture,
and the clinic due to their broad antimicrobial spectrum, oral
availability, and low cost (Walsh, 2003; Thaker et al., 2010). Tet-
racyclines are polyketide natural products of actinomycete
secondary metabolism, and have likely existed in the environ-
ment for millions of years (Baltz, 2007). Accordingly, tetracycline
resistance is expected to be an ancient feature of environmental
bacteria (D’Costa et al., 2011).
Intensive clinical and agricultural use over the past 65 years
has selected for the expansion of tetracycline resistance in envi-
ronmental microorganisms (Knapp et al., 2010), human and
animal commensals (Johnson and Adams, 1992), and among
bacterial pathogens (Chopra and Roberts, 2001). In the case of888 Chemistry & Biology 22, 888–897, July 23, 2015 ª2015 Elsevier Lhuman pathogens, tetracycline resistance is typically acquired
via horizontal gene transfer and occurs almost exclusively by
ribosomal protection or antibiotic efflux (Thaker et al., 2010; Cho-
pra and Roberts, 2001). Both of these resistance mechanisms
have their evolutionary origins in the environment (Aminov and
Mackie, 2007; Allen et al., 2010; Davies and Davies, 2010), but
are now found widely distributed in many commensal and path-
ogenic bacteria (Gibson et al., 2015;Moore et al., 2013; Forsberg
et al., 2012).
Ribosomal protection and drug efflux do not affect the con-
centration or activity of the tetracycline molecule itself, a feature
that distinguishes clinical tetracycline resistance from that of the
natural-product aminoglycoside, amphenicol, and b-lactam an-
tibiotics, which are typically inactivated enzymatically (Walsh,
2003). Bacteria expressing drug-inactivating enzymes need act
only once on a substrate to eliminate toxicity, rather than
requiring continual activity in the presence of a drug for survival
(Walsh, 2000). Despite this apparent advantage, only three
genes have ever been reported to inactivate tetracycline (Non-
aka and Suzuki, 2002; Diaz-Torres et al., 2003; Park and Levy,
1988; Speer and Salyers, 1988), and only one enzyme, Tet(X),
has been confirmed for activity in vitro (Yang et al., 2004; Moore
et al., 2005; Volkers et al., 2011). These efforts have demon-
strated that Tet(X) is a flavoprotein monooxygenase that inacti-
vates tetracycline antibiotics by monohydroxylation followed
by spontaneous, non-enzymatic breakdown (Yang et al., 2004;
Moore et al., 2005; Volkers et al., 2011).
The only report of human pathogens with the potential to inac-
tivate tetracycline occurred in 2013; 11 isolates from urinary tract
infections in Sierra Leone were positive for tet(X) (Leski et al.,
2013). At present, tetracycline inactivation is rarely detected in
environmental metagenomes (Thaker et al., 2010; Nesme
et al., 2014), indicating that it is either a truly rare function or
occurs via the activity of cryptic genes, unrecognizable as resis-
tance-conferring based on sequence composition. Because
other natural-product antibiotics are frequently inactivated enzy-
matically (Walsh, 2000, 2003; Davies, 1994), we hypothesize that
tetracycline inactivation may also be widespread, but underesti-
mated using standard methods for resistance gene prediction
from metagenomic sources.
Flavoenzymes, which include monooxygenases such as
Tet(X), are common in nature and catalyze an enormous range
of chemical transformations, including multiple modifications of
aromatic polyketides (Walsh and Wencewicz, 2013; Aminov,
2009). Their sequence diversity makes a priori functionaltd All rights reserved
Figure 1. Tetracycline-Inactivating Proteins
(A) Ten proteins derived from soil metagenomes
and four tetracycline-inactivating proteins from
NCBI. Numbers following NCBI sequences
indicate GenBank identifiers. Tet(56) was cloned
from Legionella longbeachae. Asterisks denote
nodes with Shimodaira-Hasegawa-like branch
supports >0.95, and circles denote nodes with
support >0.7. Blue labels indicate proteins with
86% amino acid identity to one another. The scale
bar represents the number of substitutions per site.
(B) The minimum inhibitory concentrations of
E. coli heterologously expressing the indicated
proteins.
(C) Absolute tetracycline levels in medium condi-
tioned by E. coli strains expressing the designated
proteins. ‘‘Theoretical Max’’ indicates the initial
tetracycline concentration in the medium prior to
inoculation.prediction a challenge, while their proclivity for horizontal gene
transfer and gene duplication allow for facile acquisition of new
function and hinder efforts to accurately measure prevalence
(Walsh and Wencewicz, 2013; Aminov, 2009). Therefore, these
enzymes may be undersampled relative to many other bacterial
functions, and represent a potential source of undiscovered anti-
biotic-inactivating enzymes. Here, we describe the functional
discovery and biochemical characterization of a novel family of
tetracycline-inactivating flavoenzymes, previously unrecogniz-
able as antibiotic resistance genes by primary sequence.
RESULTS
A Family of Novel Tetracycline Resistance Genes
We identified a family of putative flavin adenine dinucleotide
(FAD)-dependent monooxygenases through functional metage-
nomic selections for tetracycline resistance from 18 grassland
and agricultural soils (Forsberg et al., 2014). Of the ten full-length
open reading frames (ORFs) predicted (Table S1), nine were
subcloned into an Escherichia coli expression system (Table
S2) and confirmed to provide tetracycline resistance at concen-
trations up to 256 mg/ml, 64-fold greater than that of an empty-
vector control (Figure 1B). All ORFs conferred comparably high
levels of resistance toward oxytetracycline, two conferred mod-
erate resistance to minocycline, and none were active against
tigecycline (Table 1). The novel tetracycline resistance proteins
share moderate similarity with one another (average pairwise
amino acid identity 65.4% ± 9.2%) but have primary sequence
unlike any previously identified tetracycline-inactivation protein
(Figure 1A; amino acid identity to Tet(X) is at most 24.4%). Ho-Chemistry & Biology 22, 888–897, July 23, 2015mology modeling of these enzyme se-
quences predicts structural similarity to
many flavin-dependent oxidoreductases,
and indicates functional homology with
Tet(X) (Volkers et al., 2011; Kelley and
Sternberg, 2009). Therefore, we hypothe-
sized that these genes encode tetracy-
cline-inactivating flavoenzymes due to
(1) structural similarity to Tet(X), (2) their
putative FAD-binding and oxidoreduc-tase function (Diaz-Torres et al., 2003; Yang et al., 2004), and
(3) the capacity of E. coli transformants to darken growth
medium upon tetracycline addition (Figure 2), consistent with
previous observations for Tet(X) (Yang et al., 2004).
The Novel Genes Inactivate Tetracycline in
Escherichia coli
We tested the capacity for each protein to inactivate tetracy-
cline in E. coli. We grew strains of E. coli expressing each
enzyme in tetracycline-containing medium and subsequently
monitored the growth of a tetracycline-susceptible control strain
in conditioned supernatants. Unconditionedmedium, or medium
conditioned with E. coli expressing a transporter that confers
non-enzymatic tetracycline resistance, did not support the
growth of the tetracycline-susceptible control strain. Medium
conditioned by every putative flavoenzyme permitted robust
growth of the susceptible strain, indicating that the expressed
ORFs inactivate tetracycline (Figure S1). Confirming this obser-
vation, absolute quantification of tetracycline by liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) revealed
concentrations of the antibiotic up to 270-fold lower in medium
incubated with E. coli expressing a putative inactivating protein
compared with medium conditioned with E. coli expressing the
transporter (Figure 1C).
Of the nine confirmed tetracycline-inactivating proteins, five
were from agricultural soils and four from grassland soils (Fors-
berg et al., 2014), suggesting that this antibiotic resistance
gene family is distributed across diverse soil types. Only two
recognizable sequence homologs exist in NCBI_nr, both of
which are predicted oxidoreductases and neither have beenª2015 Elsevier Ltd All rights reserved 889
Table 1. Activity Profiles of Various Flavoenzymes Used in this Study
Enzyme Source
MIC Conferred to E. coli (mg/ml) In Vitro Enzyme Activity
Versus
Tetracycline
Versus
Oxytetracycline
Versus
Minocycline
Versus
Tigecycline
Activity Versus
TET/OX
Activity Versus
aTC
Production of
m/z = 387
Production of
m/z = 461
Tet(47) Soil S08 512 >512 8 2 ND ND ND ND
Tet(48) Soil S08 256 512 8 2 No No +/ +/
Tet(49) Soil S11 512 >512 8 2 Yes No ++ +/
Tet(50) Soil S11 512 256 8 2 Yes No ++ +
Tet(51) Soil S14 256 512 8 2 Yes No ++ +++
Tet(52) Soil S14 512 256 8 2 Yes No +++ +
Tet(53) Soil S15 512 256 32 2 ND ND ND ND
Tet(54) Soil S19 256 512 8 2 Yes No + +/
Tet(55) Soil S20 128 256 16 2 Yes No ++ ++
Tet(56) Legionella
longbeachae
256 256 8 2 Yes No ++ ++
Tet(X) NA 256 256 32 8 Yes Yes ++ +++
Empty
vector
NA 8 32 8 2 NA NA NA NA
Values in bold and underlined signify antibiotic resistance.
Source soils identified as in Forsberg et al. (2014).
The number of (+) symbols correspond to the amount of the indicated product detected from enzymatic tetracycline decay, as per Figure S4. (+/)
indicates that only trace amounts of product were detected.
aTC, anhydrotetracycline; MIC, minimum inhibitory concentration; NA, not applicable; ND, not determined; OX, oxytetracycline; TET, tetracycline.implicated in tetracycline resistance. Both homologs were found
in soil-dwelling bacteria, one in Rhizobacter sp. (GenBank:
646785269) and a second in Legionella longbeachae (GenBank:
289165997), a causal agent of the potentially fatal Pontiac fever
and Legionnaires’ disease (Whiley and Bentham, 2011; Cazalet
et al., 2010). The homolog from L. longbeachae conferred tetra-
cycline resistance to E. coli at levels 64-fold higher than an
empty-vector control and also functioned via drug inactivation
(Figures 1, 2, and S1).
Enzymes Inactivate Tetracycline In Vitro
Each putative tetracycline-inactivating enzyme was purified as
previously described (Yang et al., 2004). When assayed by
UV-visible spectroscopy, seven of the eight purified flavoen-
zymes appeared to degrade tetracycline with a dependence
on time, enzyme, and reduced nicotinamide adenine dinucleo-
tide phosphate (NADPH) (Figure 3). In assay conditions similar
to those in previous work (Yang et al., 2004; Moore et al.,
2005), we show reduction in absorbance at 363 nm with reac-
tions using (1) six of the seven purified soil-derived inactivating
enzymes, (2) the homolog from L. longbeachae, and (3) Tet(X)
as a positive control, indicating disruption of the b-diketone
chromophore of tetracycline (Yang et al., 2004; Moore et al.,
2005; Volkers et al., 2011). This spectral change is not observed
for reactions performed with a vector-only control for co-purified
native E. coli protein, or for those lacking enzyme (Figures 3J
and 3K). An NADPH regenerating system was used in reactions.
Although the absorbance spectrum of NADPH overlaps
with that of tetracycline (Yang et al., 2004; Moore et al., 2005),
it does not change with time (Figure 3L), and thus does
not contribute to the observed reduction in absorbance at
363 nm. The decrease in absorbance at 400 nm further indicates890 Chemistry & Biology 22, 888–897, July 23, 2015 ª2015 Elsevier Ltetracycline loss, since tetracyclines, but not NADPH, absorb at
this wavelength.
Tetracycline Inactivation Proceeds via
Diverse Mechanisms
The progression of each reaction was also monitored by
reverse-phase high-performance liquid chromatography
(HPLC) (Figures 4, S2, and S3). The tetracycline substrate
disappeared with time in all but one enzyme-catalyzed exper-
iment. In some cases tetracycline was replaced by new prod-
uct peaks (e.g. Figures 4B–4D) and in others the substrate was
eliminated without obvious signatures of new, stable products
(e.g. Figure 4A). When these reactions were analyzed by LC-
MS, the major new product gave an m/z value of 461 (com-
pound 1), equivalent to the addition of oxygen to tetracycline
(m/z for [M + H]+ equals 445 in positive ion mode). Relative
proportions of ion counts for the tetracycline substrate and
compound 1 were routinely mirrored by the relative heights
of the corresponding HPLC peaks over time (Figures 4, S2–
S4), further suggesting that the monooxygenation of tetracy-
cline is a direct result of flavoenzyme activity. This mechanism
is consistent with the reported activity of Tet(X) (Yang et al.,
2004; Moore et al., 2005; Volkers et al., 2011) and with our
empirical observations using the enzyme (e.g. Figures 4D
and 4I). In cases where no stable product was observed by
HPLC (e.g. Figure 4A), no ion with an m/z value of 461 was
observed (e.g. Figure 4F) despite the obvious disappearance
of tetracycline. This indicates that some flavoenzymes may
degrade tetracycline using mechanisms different from Tet(X).
When tested for activity against anhydrotetracycline (the final
precursor in tetracycline biosynthesis), Tet(X), but none of
the discovered flavoenzymes, could oxidize the substratetd All rights reserved
Figure 2. Expression of Tetracycline-Inactivating Genes Darkens
Tetracycline-Containing Growth Media
E. coli transformants expressing either a tetracycline-resistant transporter or
the indicated tetracycline-inactivating protein were grown in Luria-Bertani
broth at 37C for 4 days, protected from light. The same cultures expressing
the tetracycline-resistant transporter are used across each image. Tetracy-
cline was added at 100 mg/ml except for Tet(55); 32 mg/ml tetracycline was
added to this sample due to a lower degree of tetracycline resistance
conferred by this enzyme.(Figure 5), reinforcing observations that these enzymes can act
distinctly from Tet(X).
In addition to the appearance of a monooxygenated tetracy-
cline, enzymatic reactions showed the appearance of a structure
with anm/z value of 387 (compound 2) as the reaction progressed
(Figures 4, S4, and S5). Similarly to the monooxygenated prod-
uct, this ion often replaced the tetracycline substrate over time
but did not readily absorb light at the wavelengths examined.
We propose two putative mechanisms whereby a product with
thismassmay accumulate via either a Baeyer-Villiger ring expan-
sion or a Grob fragmentation of tetracycline, producing an unsta-
ble oxidized product that rapidly decomposes to compounds 2a
and 2b (Figure S6). High-resolution tandem MS of tetracycline
degradation reactions produce fragmentation patterns that are
consistent with our proposed structures for compounds 2a/2b
and with the ions observed by LC-MS (Figures 6 and S5). The
relative abundances of the major enzymatic products (m/z =
461, compound 1 and m/z = 387, compounds 2a/2b) were
dependent on enzyme, and consistent across experiments and
analytical methods (Figures 4, S4, S5; Supplemental Dataset 1).
Consistent enzymatic preference for production of compound 1
versus compounds 2a/2b indicates that these flavoenzymes
can differ in their favored mechanism of oxidizing tetracycline
(Table 1).
Purified flavoenzymes were also examined for their ability to
degrade the substrate oxytetracycline (Figures S2, S3, S7).
Tet(X) hydroxylated oxytetracycline, as previously describedChemistry & Biology 22,(Yang et al., 2004). Similar to the results achieved using tetracy-
cline, the flavoenzymes from soil and L. longbeachae appeared
to degrade oxytetracycline into diverse oxidation products,
some consistent with the known activity of Tet(X) and others
via potentially different oxidation mechanisms. Tetracyclines ul-
timately degrade into a heterogeneous mixture of poorly defined
(and perhaps polymeric) structures via abiotic and, in the case of
Tet(X), enzymatic processes (Yang et al., 2004; Chen and Huang,
2011; Jeong et al., 2010; Palmer et al., 2010). Our results are
consistent with these observations. Reverse-phase HPLC using
tetracycline and oxytetracycline antibiotics showed the disap-
pearance of characteristic substrate absorbances at 260 and
363 nm, indicating that conjugation in both the b-tricarbonyl
and aryl b-diketone chromophores was disrupted (Figures S2
and S3). In addition, HPLC and MS analyses reveal a heteroge-
neous product mixture at late time points (Figures 4, S2, and S3),
consistent with the observation of many small peaks in the chro-
matograms andmolecular ion features with diversem/z values at
low to moderate abundance (Supplemental Dataset 1).
DISCUSSION
Widespread tetracycline use has fueled concerns that tetracy-
cline residues and their decay products may persist in milk
(levels measured at >2 mg/l [de Albuquerque Fernandes et al.,
2014]), wastewater (Novo et al., 2013), the food supply (Silber-
geld et al., 2008), and agricultural settings (Zhu et al., 2013).
Tetracycline use is particularly heavy in livestock rearing (Zhu
et al., 2013), with estimates that tetracyclines account for two-
thirds of total therapeutic antibiotic use in animals (Ungemach
et al., 2006). Tetracycline concentrations in wastewater (Novo
et al., 2013) and livestockmanure (Zhu et al., 2013) directly corre-
late with shifts in microbial community composition and in-
creases in antibiotic resistance. The increased recognition of
tetracycline as a pollutant (Chen and Huang, 2011) has sparked
renewed interest in understanding its decay processes for pre-
dicting persistence in contaminated environments (Aga et al.,
2005) and for use in water treatment facilities (Jeong et al.,
2010). Our results highlight the diverse repertoire of tetracy-
cline-degrading enzymes relevant to these efforts, likely stem-
ming from long-standing evolutionary processes reflective of
the intimate role of tetracycline in soil microbial ecology (Thaker
et al., 2010; Baltz, 2007; D’Costa et al., 2011; Chopra and Rob-
erts, 2001; Bassett et al., 1980).
Screening environmental isolates for bioactive secondary me-
tabolites detects tetracycline production from approximately 1 in
1,000 actinomycetes (Baltz, 2007). Biosynthesis of tetracycline is
ancient (Bassett et al., 1980), resulting in numerous enzymes
capable of modifying tetracycline scaffolds (Pickens and Tang,
2009; D’Costa et al., 2006) while selecting for diverse resistance
genes over long time spans (D’Costa et al., 2011) and across
many habitats (Thaker et al., 2010; Chopra and Roberts, 2001;
Roberts, 2012). Because antibiotics and their decay products
can affect microbial communities in complex manners (e.g.
tetracycline degradation selects for drug sensitivity [Palmer
et al., 2010] and antibiotics can act as signaling molecules
[Davies and Davies, 2010; Yim et al., 2007]), environmental se-
lection for tetracycline degradation likely includes processes
both related to, and independent of, the drug’s role in microbial888–897, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 891
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Figure 3. UV-Visible Spectrum of Enzymatic
Tetracycline Degradation
(A–L) Each panel shows the degradation of tetra-
cycline over the course of 3 hr, in a reaction con-
taining the indicated purified enzyme (or control),
tetracycline, and an NADPH regeneration system.
Absorbance scans were taken at 1-min intervals.
The rainbow pattern depicts a spectral change
over time; absorbance at 360 or 400 nm always
decreased with time. See also Figure S7.warfare. Despite these myriad pressures for tetracycline decay,
enzymes that inactivate tetracycline are rarely identified (Nonaka
and Suzuki, 2002; Diaz-Torres et al., 2003; Park and Levy, 1988;
Speer and Salyers, 1988). In contrast, enzymes that inactivate
other natural-product antibiotics are common (Walsh, 2000,
2003). Our discovery of a novel family of tetracycline-inactivating
enzymes helps to address this disparity, and suggests that enzy-
matic tetracycline inactivation may be a feature of natural soil
habitats more widely distributed than previously recognized.
Examining diverse soil metagenomes will likely uncover more
tetracycline-inactivating enzymes, including additional flavin
monooxygenases and, perhaps, enzymes of undescribed activ-
ity (e.g. dioxygenases, which, like monooxygenases, can oxidize
polyketides and are important in the biosynthesis of tetracy-
cline’s ring structure [Zhang et al., 2008; Wang et al., 2009]).
Coincident with anthropogenic antibiotic use, resistance gene
abundances have increased in environmental, commensal, and
pathogenic bacteria, often disseminating through microbial
populations via horizontal gene transfer (Knapp et al., 2010;
Johnson and Adams, 1992; Chopra and Roberts, 2001). Relative
to the staggering diversity of antibiotic resistance genes in the
environment (Allen et al., 2010; Nesme et al., 2014; Forsberg
et al., 2014; Allen et al., 2009; Pehrsson et al., 2013), resistance
in human pathogens is typically encoded by amuch smaller pool
of circulating resistance genotypes (Davies and Davies, 2010;
Roberts, 2012; Jacoby and Munoz-Price, 2005). The clinical re-
sistome may be driven by the initial stochastic acquisition of892 Chemistry & Biology 22, 888–897, July 23, 2015 ª2015 Elsevier Ltd All rights reservedresistance genes, followed by antibiotic-
induced selection pressure for clonal
expansion and subsequent diversification
(Canton and Coque, 2006; Woodford and
Ellington, 2007). This leads to a ‘‘founder-
effect’’ scenario: once a particular resis-
tance mechanism is widely distributed
within pathogenic bacteria, a gene
conferring similar function in the environ-
ment is less likely to outcompete estab-
lished pathogen resistance genes for the
same niche (Martinez et al., 2015). In
contrast, resistance genes that can
confer a fitness advantage by targeting
an unfilled niche (e.g. novel activity or
expanded substrate spectrum) represent
larger threats for entering the circulating
pathogenic resistome (Canton and Co-
que, 2006; Munoz-Price et al., 2013; Dor-
tet et al., 2014).By this reasoning, enzymes that inactivate tetracycline antibi-
otics may present clinical concern: drug inactivation is a
preferred mechanism of pathogens to resist many antibiotics
(Walsh, 2003; Davies, 1994), which is thus far scarcely observed
for tetracycline. The success in clinical trials of eravacycline, a
broad-spectrum fluorocycline minimally affected by tetracycline
efflux or ribosomal protection resistance mechanisms (Sutcliffe
et al., 2013), reinforces the importance of surveillance for tetracy-
cline-inactivating enzymes. The canonical tetracycline-inactiva-
tion gene, tet(X), has been reported in pathogens only once (Leski
et al., 2013), but has been identified on multiple transposable
elements (Park and Levy, 1988; Speer and Salyers, 1988) and
in multiple bacterial phyla (Yang et al., 2004; Leski et al., 2013;
Ghosh et al., 2009). Directed evolution of Tet(X) suggests it may
rapidly acquire strong resistance-conferring phenotypes (Wal-
kiewicz et al., 2010), and its dissemination potential via horizontal
gene transfer is consistent with the promiscuity of flavoprotein
monooxygenases (Walsh and Wencewicz, 2013; Aminov, 2009).
Our results indicate that Tet(X) is not alone. From six soil meta-
genomes, we identified nine predicted flavoenzymes that inacti-
vate tetracycline when expressed heterologously in E. coli, five
from agricultural soils and four from grassland soils. These soils
have no history of anthropogenic tetracycline addition (Fierer
et al., 2012; Ramirez et al., 2010), suggesting that these enzymes
represent native functional capacities of soil bacteria. The newly
discovered flavoenzymes confer resistance against multiple
tetracycline antibiotics and have a homolog in the soil-dwelling
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Figure 4. Tetracycline Degradation Is Catalyzed by Diverse Flavoenzymes
(A–E) Reverse-phase HPLC separation of tetracycline and enzymatically catalyzed degradation products; absorbance at 260 nm is shown.
(F–J) The relative ion counts attributable to tetracycline (m/z for [M + H]+ equals 445 in positive ion mode) and products with m/z values of 461 and 387; data
generated from the same reactions depicted in (A–E). The replacement of tetracycline with a product of +16 Da is consistent with monooxidation of the antibiotic
and themechanism through which Tet(X) catalyzes its degradation (Yang et al., 2004). A putative structure for the product withm/z = 387 is proposed in Figures 6
and S6. Flavoenzymes from soil catalyze tetracycline degradation in manners both consistent with (e.g. B, G) and alternative to (e.g. A, F) Tet(X)-mediated
catalysis (D, I). Data from experiments using all purified enzymes, oxytetracycline as substrate, andmeasurements of absorbance at 363 nm are shown in Figures
S2–S4, and S7.human pathogen L. longbeachae, which was also confirmed
to inactivate tetracycline when expressed in E. coli. Seven of
these enzymes were successfully purified and shown to catalyt-
ically inactivate tetracycline via UV-visible spectroscopy. When
examined by reverse-phase HPLC, LC-MS, and high-resolution
tandem MS, reactions using different enzymes yielded distinct
product profiles, only some of which resembled that of a reac-
tion using Tet(X). This suggests that the soil-derived enzymes
degrade tetracycline via diverse oxidative mechanisms,
including strategies distinct from the established hydroxylation-
mediateddecayusedbyTet(X). Because these enzymes function
to confer tetracycline resistance inE. coli, their degradation prod-
ucts are not likely to be antibacterial at levels comparable with
those of tetracycline itself. Whether these tetracycline-derived
metabolites select for drug sensitivity like some abiotic tetracy-
cline decay products (Palmer et al., 2010), can act as signaling
molecules (Davies and Davies, 2010; Yim et al., 2007), or other-
wise affect the structure or dynamics of soil microbial commu-
nities warrants additional work.
Tetracycline-inactivating flavoenzymesare not onlydistributed
across diverse soils, but may also traverse diverse phylogenetic
lineages. In twoof tenmetagenomic contigs (Table S1), a tetracy-
cline-inactivating gene was immediately downstream of a gene
predicted to encode an aminoglycoside-resistant kinase and
upstream of a predicted virulence factor in one contig and aChemistry & Biology 22,predicted resolvase in the other (Forsberg et al., 2014). These
annotations are consistent with functions often present in multi-
drug-resistant mobile genetic elements (Sengupta and Austin,
2011; Cordero and Polz, 2014) and highlight the dissemina-
tion potential of these flavoenzymes (Aminov, 2009). A tetracy-
cline-resistant flavoenzyme was found encoded in the human
pathogen L. longbeachae but not its close relative Legionella
pneumophila, indicating that tetracycline inactivation may be a
flexible, mobile component of this pathogen’s genome. Like
other pathogens implicated in the rapid acquisition of multidrug
resistance (e.g.Acinetobacter, Pseudomonas),Legionella thrives
in both environmental and infectious settings (Whiley and Ben-
tham,2011;Cazalet et al., 2010) and is amemberof a larger group
of generalist Proteobacteria implicated in the exchange of antibi-
otic resistance between soil and clinic (Forsberg et al., 2012,
2014). Although theflavoenzymesdescribedherein likely evolved
in response to environmental selection pressures (e.g. tetracy-
cline production by soil microbes), they should be carefully moni-
tored due to their association with many of the risk factors
predicted to promote acquisition by human pathogens.
SIGNIFICANCE
Enzymes that inactivate most naturally derived antibiotics,
but not tetracycline, are commonly found in environmental888–897, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 893
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Figure 5. Tet(X), but No Other Flavoenzyme, Oxidizes Anhydrotetracycline
(A–E) Representative UV-visible spectra; each panel shows absorbance spectra taken every 30min throughout a 3.5-hr reaction with anhydrotetracycline and the
indicated enzyme. The legend in (E) applies to (A–E); Tet(X) was the only flavoenzyme to show activity toward anhydrotetracycline.
(F–J) The relative ion counts attributable to anhydrotetracycline (m/z for [M + H]+ equals 427 in positive ion mode) and a product with +16 Da, consistent with
monooxidation of the substrate.
(K–M) Representative LC-MS spectra of the indicated ions in from (I), measured at 3.5 hr as indicated in red. TIC, total ion count; EIC, extracted ion count.and clinical settings. We reconcile tetracycline’s apparent
outlier statuswith thediscovery of ten tetracycline-inactivat-
ing enzymes, previously unrecognizable as resistance genes
on the basis of primary sequence. This family of flavoen-
zymes was confirmed to inactivate tetracycline in vitro and
includes members that degrade the antibiotic via known,
as well as previously uncharacterized, oxidative mecha-
nisms. Enzymes were identified from multiple soil types,
across varied geography, and from diverse phylogenetic
origin, including from a causal agent of Pontiac fever and
Legionnaires’ disease, Legionella longbeachae. Because
some of these enzymes show genetic signatures indicative
of horizontal gene transfer, their potential for movement
into hospital settings should be carefully monitored.
EXPERIMENTAL PROCEDURES
A full description of experimental procedures is provided in Supplemental
Experimental Procedures.
Determination of Tetracycline Inactivation in E. coli
Each ORF encoding a putative tetracycline-inactivating enzyme was subcl-
oned from its metagenomic (or genomic) source into the pZE21 expression894 Chemistry & Biology 22, 888–897, July 23, 2015 ª2015 Elsevier Lvector (Lutz and Bujard, 1997) and transformed into E. coli MegaX cells
(Invitrogen). Minimum inhibitory concentrations were determined using Muel-
ler-Hinton broth and profiled via absorbance measurements at 600 nm
(OD600) using the Synergy H1 microplate reader (Biotek Instruments) for a
minimum of 48 hr at 37C. Luria-Bertani broth was used for darkened me-
dium and Mueller-Hinton broth for conditioned medium experiments. Initial
inocula were normalized across samples, and OD600 measurements used
to profile tetracycline susceptibility in conditioned medium experiments using
the Synergy H1 microplate reader. Tetracycline levels in supernatants of
liquid growth assays were quantified via LC-MS/MS by Dr. Sophie Alvarez
of the Proteomics and Mass Spectrometry Facility at the Donald Danforth
Plant Science Center (St. Louis, MO, USA). Tetracycline quantification as-
says were performed using M9 minimal salts medium and PIPES (Sigma
#P6757) as an internal standard.
Enzyme Purification
All genes encoding putative tetracycline-inactivating enzymes were cloned
into the pET28b(+) vector (Novagen) at BamHI and NdeI restriction sites.
Constructs were then transformed into BL21-Star(DE3) E. coli cells (Life Tech-
nologies) and expression induced with isopropyl b-D-1-thiogalactopyrano-
side. Enzymes were expressed with an N-terminal His6-tag and purified via
Ni-NTA (nitrilotriacetic acid) resin, concentrated by centrifugal filtration using
a 10-kDa molecular weight cutoff size-based concentration column (Millipore
cat #ACK5010PG), analyzed by SDS-PAGE for purity, quantified by A280
measurement, flash-frozen in liquid nitrogen as 50-ml aliquots, and stored
at 80C.td All rights reserved
Figure 6. Enzymatic Conversions Discussed in this Article
(A) Monooxygenation of tetracycline to compound 1, as described by Yang et al. (2004).
(B) The proposed tetracycline oxidation products, compounds 2a and 2b, with an m/z value of 387.
(C) Monooxygenation of anhydrotetracycline, depicted as is described for Tet(X)-catalyzed oxidation of tetracyclines in Yang et al. (2004).In Vitro Determination of Tetracycline Inactivation
All reactions were performed using 100 mM TAPS buffer (pH 8.5) unless
otherwise noted. Inactivation reactions contained 1.4 mM antibiotic, 350 mg
enzyme, and an NADPH regenerating system in a total volume of 564 ml. For
reactions using anhydrotetracycline, 1 mM substrate was used with 200 mg
enzyme in a 475-ml reaction. The NADPH regenerating system consisted of
the following components (final concentrations): glucose-6-phosphate
(40mM), NADP+ (4 mM), MgCl2 (1 mM), and glucose-6-phosphate dehydroge-
nase (4 U/ml). The regeneration system was incubated at 37C for 30 min to
generate NADPH before use in reactions. Immediately upon reaction initiation,
aliquots were diluted 40-fold (50-fold with anhydrotetracycline) and scanning
UV-visible spectroscopy measurements taken from 280- to 550-nm wave-
length light with a Cary 60 UV/Vis system (Agilent) for at least 3 hr. Reactions
were subsequently sampled at indicated time points by transferring a 50-ml
volume into a 200-ml quencher solution comprising equal parts of acetonitrile
and 0.25 M aqueous HCl. Reactions were quenched under acidic conditions
because prior work with Tet(X) demonstrated that enzymatic degradation
products of tetracyclines are unstable at neutral pH but stable at low pH
(Yang et al., 2004; Moore et al., 2005).
Products generated from enzymatic inactivation of both tetracycline and
oxytetracycline were separated by reverse-phase HPLC using a Phenom-
enex Luna C18 column (5 mm, 110 A˚, 2 3 50 mm) and 0.1% trifluoroacetic
acid in water (A) and acetonitrile (B) as mobile phase. Injections of 25 ml
sample volume were eluted using a linear gradient from 25%B to 75%B
over 14 min at a flow rate of 1 ml/min. Samples were analyzed by LC-MS us-
ing an Agilent single-quadrupole LC/MS 6130 fitted with an autosampler and
diode array detector. Reaction products were first separated by reverse-
phase HPLC using a Phenomenex Gemini C18 column (5 mm, 110 A˚, 2 3Chemistry & Biology 22,50 mm) and 0.1% formic acid in water (A) and acetonitrile (B) as mobile
phase. Injections of 30 ml sample volume were eluted using a linear gradient
of 0%B to 95%B over 14 min at a flow rate of 0.5 ml/min. Electrospray ioni-
zation was used for analysis of reaction products by MS and ion counts for a
particular m/z peak determined by peak height. Panels in Figures 4, S4, and
S5 depict ion counts of various analytes from each enzymatic (or control)
reaction, normalized to the counts observed for the peak associated with
the tetracycline substrate (m/z of 445) at the first time point taken (5 min after
reaction initiation).
Reactions performed for high-resolution tandem MS were prepared as
described above and 45-min time points used for analysis. Samples were
diluted 6-fold with 50%MeOH/0.1% formic acid and run on LTQ-Orbitrap Ve-
los by direct infusion using the Advion Triversa Nanomate. The samples were
acquired using a high-resolution (60,000) mass spectrometer. The MS scan
was acquired from 300 to 550 m/z. The 387 m/z compound was fragmented
by MS2 and MS3-CID with collision energies of 15 and 25 eV, respectively.ACCESSION NUMBERS
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